Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$5.93 +7.6%	$4.12	$1.38 ▼ $18.74	$162.58M	1.51	688,609 shs	1.27 million shs
DTIL Precision BioSciences	$4.38 +2.7%	$4.91	$3.61 ▼ $11.09	$48.52M	1.43	224,058 shs	61,346 shs
OYST Oyster Point Pharma	$11.17	$11.15	$3.46 ▼ $19.00	$299.85M	1.31	212,171 shs	330 shs
PSTX Poseida Therapeutics	$9.50	$9.48	$2.32 ▼ $9.67	$928.85M	1.63	1.05 million shs	N/A
SLDB Solid Biosciences	$4.98 +2.2%	$3.79	$2.41 ▼ $10.37	$385.69M	2.34	1.19 million shs	702,337 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+7.62%	+20.77%	+18.60%	+280.13%	-59.19%
DTIL Precision BioSciences	+2.70%	+5.68%	-15.05%	-5.10%	-52.86%
OYST Oyster Point Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
PSTX Poseida Therapeutics	0.00%	0.00%	0.00%	0.00%	+223.13%
SLDB Solid Biosciences	+2.18%	+3.45%	+42.17%	+59.49%	-16.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	4.292 of 5 stars	3.2	4.0	0.0	4.6	2.0	1.7	0.6
DTIL Precision BioSciences	4.519 of 5 stars	3.5	3.0	0.0	4.6	2.3	1.7	1.3
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PSTX Poseida Therapeutics	0.503 of 5 stars	1.0	0.0	0.0	4.6	0.6	0.8	0.0
SLDB Solid Biosciences	3.4364 of 5 stars	4.6	2.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.33	Hold	$14.00	136.09% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	974.29% Upside
OYST Oyster Point Pharma	0.00	N/A	N/A	N/A
PSTX Poseida Therapeutics	2.00	Hold	$9.50	N/A
SLDB Solid Biosciences	3.17	Buy	$15.10	203.46% Upside

Current Analyst Ratings Breakdown

Latest PSTX, SLDB, OYST, AGEN, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$99.52M	1.63	N/A	N/A	($13.06) per share	-0.45
DTIL Precision BioSciences	$68.70M	0.71	N/A	N/A	$6.87 per share	0.64
OYST Oyster Point Pharma	$24.54M	12.22	N/A	N/A	$3.80 per share	2.94
PSTX Poseida Therapeutics	$150.86M	6.16	N/A	N/A	$1.08 per share	8.80
SLDB Solid Biosciences	$8.09M	47.67	N/A	N/A	$3.43 per share	1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$227.21M	-$8.67	N/A	N/A	N/A	-196.12%	N/A	-82.33%	8/6/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
OYST Oyster Point Pharma	-$100.66M	-$6.65	N/A	N/A	N/A	-901.99%	-490.33%	-108.29%	N/A
PSTX Poseida Therapeutics	-$123.43M	-$0.63	N/A	N/A	N/A	-40.28%	-72.26%	-21.53%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest PSTX, SLDB, OYST, AGEN, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A
PSTX Poseida Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.11	0.11
DTIL Precision BioSciences	0.45	6.62	6.62
OYST Oyster Point Pharma	8.49	3.35	3.11
PSTX Poseida Therapeutics	0.68	3.20	3.20
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
DTIL Precision BioSciences	37.99%
OYST Oyster Point Pharma	96.70%
PSTX Poseida Therapeutics	46.87%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	5.50%
DTIL Precision BioSciences	4.50%
OYST Oyster Point Pharma	17.90%
PSTX Poseida Therapeutics	2.90%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
DTIL Precision BioSciences	200	11.09 million	10.59 million	No Data
OYST Oyster Point Pharma	303	26.84 million	22.04 million	Not Optionable
PSTX Poseida Therapeutics	260	97.77 million	94.94 million	Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable

PSTX, SLDB, OYST, AGEN, and DTIL Headlines

Recent News About These Companies

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2 at 8:04 AM | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1 at 4:05 PM | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at Citigroup

June 29, 2025 | americanbankingnews.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at Citigroup

June 27, 2025 | marketbeat.com

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives $14.90 Consensus PT from Analysts

June 24, 2025 | americanbankingnews.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC Wainwright

June 17, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

Brokers Offer Predictions for SLDB FY2026 Earnings

June 10, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Solid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP Securities

June 6, 2025 | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

PSTX, SLDB, OYST, AGEN, and DTIL Company Descriptions

Agenus NASDAQ:AGEN

$5.93 +0.42 (+7.62%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$6.01 +0.08 (+1.35%)

As of 07/3/2025 04:42 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Precision BioSciences NASDAQ:DTIL

$4.38 +0.12 (+2.70%)

Closing price 07/3/2025 03:21 PM Eastern

Extended Trading

$4.36 -0.01 (-0.23%)

As of 07/3/2025 04:33 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Oyster Point Pharma NASDAQ:OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Solid Biosciences NASDAQ:SLDB

$4.98 +0.11 (+2.18%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$5.03 +0.05 (+0.98%)

As of 07/3/2025 04:54 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time